TrialTracker_MD said:Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts.
I dislike how confidently this board tells people to push through. Incidence figures around 20 to 25% at the higher doses are class-typical, but the trials also had a discontinuation column, and "manageable with protocols" is not the same as manageable for everyone.
One concrete data point for the thread. If you are going to change something, change one thing and give it long enough to express itself. Four weeks is the usual minimum for anything pharmacological on this board, and two weeks of data has told you almost nothing.
Dr.RaviCardio said:I dislike how confidently this board tells people to push through.
There is a second half to this that has not been said yet. It helps to say which part of this you are uncertain about. A precise question gets a precise answer; a general one gets everybody’s favourite anecdote.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsFollowing on from B12Beth — and this may be the naive question:
Whether holding at a lower dose for longer actually reduces total side-effect burden or just spreads it out?
Reporting back.
Follow-up: smaller meals, less fat in the two days after dosing, and not lying down afterwards. Unglamorous, and it worked within a fortnight.